Answer

IFF Scent recovery drivers, expected H2 evolution by sub-segment, and 2027 R&D plan support

1) Drivers of Scent’s recovery (what’s working and why)

A. Fine Fragrance: managing volatility (especially Middle East) while building the recovery shape

Management attributes Scent’s Fine Fragrance performance in Q2 to strong execution in managing “the challenges in the Middle East,” with Fine Fragrance finishing “up slightly positive” versus an expectation of “growth to be down in Fine Fragrance mid-single digits.” ¹
For the remainder of 2026, the recovery is described as a “softer Q3” followed by “a stronger Q4,” with the team targeting a “mid-single-digit range” for the second half of the year for Fine Fragrance on that basis. ²
The narrative also highlights the role of difficult year-over-year comparisons: Q3 last year had Fine Fragrance growth of “20%,” making 2026 comparisons “a big comp” even as the trend is “in the right direction” into Q4. ¹

Interpretation (from the transcript): Fine Fragrance recovery appears to be less about a one-off normalization and more about (i) risk management through a volatile macro/geopolitical period and (ii) lap timing versus prior-period strength, producing a “Q3 softness / Q4 recovery” profile. ²¹

B. Consumer Fragrance: rebuild R&D capability + go-to-market to regain share

For Consumer Fragrance, management frames the second-half trajectory as a “low single-digit range,” after Q2 delivered “high single-digit” growth that is expected to “normalize” going forward to a low single-digit number. ²
The drivers emphasized for the business include rebuilding capabilities and commercial execution: the company references “rebuild the R&D capability go-to-market approach with customers, and trying to drive market share gains there.” ²
In Q2 specifically, Scent delivered “strong 8% growth,” with performance driven by “double-digit growth in Fragrance Ingredients and high single-digit increase in Consumer Fragrance.” ³

Interpretation: Consumer Fragrance recovery is described as capability- and customer-execution driven (R&D + go-to-market + share gains), with near-term growth variability from normalization after a strong Q2. ²³

C. Fragrance Ingredients: strong Q2, then normalization toward higher-value natural products

Fragrance Ingredients was a key contributor to the quarter: Scent Q2 sales were “up 8%,” driven by Fragrance Ingredients “grew north of 20%,” while noting that part of this was “year-over-year delta” versus a prior period down “10% or more.” ¹
The other part of Q2 strength is attributed to commercial leverage under difficult conditions: management says the team “strategically leveraged the synthetics portfolio” to capture more sales due to “macro… including… supply chain disruptions and higher Brent crude prices.” ¹
Going forward, the company expects normalization: as conditions settle, growth is forecast to “shift back towards the higher value-added ingredients versus the traditional synthetics,” and this shift is said to be underway with a timing note that it “will take a little bit more time, not in the second half of this year,” but rather “as we go into next year and the year after” the company expects a “really strong competitive position.” ²

Interpretation: The ingredients side is undergoing a portfolio/quality mix transition (synthetics strength in Q2 vs. higher-value natural orientation over time), with near-term growth normalizing and competitive advantage expected later (next year/2027 horizon). ²¹

D. R&D capability restoration is already in motion (and visible in the pipeline)

Management explicitly characterizes an R&D “recovery” timeline: “2.5 years ago” the “R&D pipeline… was not what it should have been,” while “today” the company says it has “a very strong R&D capability,” a “great R&D team,” “great perfumers… developing… leading-edge new Fine Fragrances and Consumer Fragrances,” plus “a great pipeline of molecules as well as delivery systems.” ⁴
They add that they are “not satisfied” but “making really good progress,” with strengthened strengths and addressed gaps, and express being “optimistic about the future of Scent.” ⁴

2) How Fine Fragrance and Consumer Fragrance will evolve in the second half (H2 2026)

Fine Fragrance (H2 outlook)

Fine Fragrance is expected to be “a little bit softer in Q3” and “a stronger Q4,” resulting in a “second half basis” growth rate “in the mid-single-digit range.” ²
The Q4 recovery framing is tied to uncertainty management and comps: Q3 is pressured by a “20%” prior-year comp, and management expects “recovery as we get to Q4 overall.” ¹

Consumer Fragrance (H2 outlook)

Consumer Fragrance is expected to be “in that low single-digit range” in the second half, with Q2 “high single-digit” growth expected to “normalize… to kind of a low single-digit number” going forward. ²
The sustainability mechanism cited is rebuilding R&D + customer go-to-market to drive market share gains (i.e., the recovery isn’t merely cyclical). ²

3) Plan for R&D to support 2027 (what’s explicitly stated)

A. 2027 support is grounded in pipeline rebuilding and execution capability

Management says the company has already rebuilt critical R&D components: “leading-edge new Fine Fragrances and Consumer Fragrances,” “pipeline of molecules as well as delivery systems,” and an overall “strong R&D capability” today compared with when the pipeline “2.5 years ago… was not what it should have been.” ⁴
This capability supports evolution into 2027 by targeting innovation capacity and product/system pipeline depth rather than only short-term demand capture. ⁴

B. Ingredients mix transition sets up competitiveness into next year and “the year after”

Although your question focuses on Fine/Consumer Fragrance and R&D, the transcript links competitive positioning into the multi-year period: Fragrance Ingredients’ shift to “higher-value natural products” is described as underway, taking more time, and leading to “a really strong competitive position” “as we go into next year and the year after.” ²
That multi-year “next year and the year after” positioning is the type of environment where R&D pipeline progress and delivery systems become more defensible by 2027. ²⁴

C. The company is explicitly reinvesting to keep the innovation “circle” going

On forward investment, management highlights that R&D is a critical continuing reinvestment element: R&D as a percentage of sales is referenced in the “8% to 9% range,” and they emphasize “critically continue to reinvest… to making sure we set ourselves apart,” describing it as a “circle” where investments enable better growth, which then allows reinvestment and supports margin expansion. ⁵
They also state “innovation matters” as a “pillar” of Remainco’s strategy going forward, which directly frames how R&D supports longer-term outcomes including 2027. ⁵

Summary (directly answering the question)

Drivers of Scent’s recovery: improved Fine Fragrance execution managing Middle East volatility, a Consumer Fragrance strategy focused on rebuilding R&D capability and customer go-to-market to regain market share, and a Fragrance Ingredients tailwind in Q2 that is expected to normalize as the company shifts toward higher-value ingredients (with competitive advantage expected later). ¹²³
H2 evolution (2026):
- Fine Fragrance: softer in Q3, stronger in Q4; mid-single-digit second-half growth. ²
- Consumer Fragrance: growth normalizes from high single-digit Q2 to low single-digit in the second half. ²
R&D plan to support 2027: the company reports that R&D capability and pipeline quality (molecules + delivery systems; leading-edge perfumer work for Fine/Consumer) have been substantially rebuilt from a weaker starting point “2.5 years ago,” and it commits to continued R&D reinvestment at 8%–9% of sales as part of a self-reinforcing innovation-and-growth strategy. ⁴⁵

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

Keep Reading

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.

Sources used

Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?

Answer outline

Drivers of Scent’s recovery (what management attributes the turnaround to)
- Rebalancing and targeted reinvestment in Scent capabilities
- R&D pipeline and leadership reset (the “capability” driver)
- Fine Fragrance vs. Middle East volatility (a major near-term driver of the recovery path)
- Consumer Fragrance execution: rebuilding R&D and go-to-market to win share
- Fragrance Ingredients: strong Q2 performance, then normalization and mix shift
How Fine Fragrance and Consumer Fragrance will evolve in 2H 2026 (management’s directional growth view)
- Fine Fragrance (soft Q3, stronger Q4; trajectory into 2H mid-single digits)
- Consumer Fragrance (low single-digit normalization; Q2 was strong but should normalize)
- What “rebuild” work is expected to contribute
Plan for R&D to support 2027 (what management says is in place and what it is designed to achieve)
- R&D capability improvement is already visible in pipeline and development capacity
- R&D is explicitly linked to business evolution: Fine/Consumer through leadership of “gaps” and strengths
- Management’s “competitive position” expectation (time horizon extending beyond 2026)
- Product development and delivery systems as the tangible R&D output
Bottom line summary (directly answering your three parts)

Keep Reading

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

Sources used

Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?

Answer outline

Drivers of Scent’s recovery (what management attributes the turnaround to)
- Rebalancing and targeted reinvestment in Scent capabilities
- R&D pipeline and leadership reset (the “capability” driver)
- Fine Fragrance vs. Middle East volatility (a major near-term driver of the recovery path)
- Consumer Fragrance execution: rebuilding R&D and go-to-market to win share
- Fragrance Ingredients: strong Q2 performance, then normalization and mix shift
How Fine Fragrance and Consumer Fragrance will evolve in 2H 2026 (management’s directional growth view)
- Fine Fragrance (soft Q3, stronger Q4; trajectory into 2H mid-single digits)
- Consumer Fragrance (low single-digit normalization; Q2 was strong but should normalize)
- What “rebuild” work is expected to contribute
Plan for R&D to support 2027 (what management says is in place and what it is designed to achieve)
- R&D capability improvement is already visible in pipeline and development capacity
- R&D is explicitly linked to business evolution: Fine/Consumer through leadership of “gaps” and strengths
- Management’s “competitive position” expectation (time horizon extending beyond 2026)
- Product development and delivery systems as the tangible R&D output
Bottom line summary (directly answering your three parts)

IFF Scent Recovery Fueled by Fine Fragrance Management and 2027 R&D Plan

Sources used

Research question

Answer

IFF Scent recovery drivers, expected H2 evolution by sub-segment, and 2027 R&D plan support

1) Drivers of Scent’s recovery (what’s working and why)

A. Fine Fragrance: managing volatility (especially Middle East) while building the recovery shape

B. Consumer Fragrance: rebuild R&D capability + go-to-market to regain share

C. Fragrance Ingredients: strong Q2, then normalization toward higher-value natural products

D. R&D capability restoration is already in motion (and visible in the pipeline)

2) How Fine Fragrance and Consumer Fragrance will evolve in the second half (H2 2026)

Fine Fragrance (H2 outlook)

Consumer Fragrance (H2 outlook)

3) Plan for R&D to support 2027 (what’s explicitly stated)

A. 2027 support is grounded in pipeline rebuilding and execution capability

B. Ingredients mix transition sets up competitiveness into next year and “the year after”

C. The company is explicitly reinvesting to keep the innovation “circle” going

Summary (directly answering the question)

References

Keep Reading

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

Keep Reading

Keep Reading

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

IFF Scent Recovery Driven by R&D Rebuild; Q2 2026 H2 Outlook and 2027 Plan

IFF's Scent Recovery Q2 2026 Highlights, H2 Outlook and 2027 R&D Plan

IFF Signals Scent Recovery Driven by R&D Rebuild and 2027 Plan

IFF Scent Recovery Driven by R&D Rebuild, Fragrance Momentum, and 2027 Plan

IFF's Scent Recovery Driven by R&D Rebuild, 2027 Readiness Ahead

IFF Scent Recovery Driven by R&D Rebuild, H2 Outlook, and 2027 Plan

IFF Scent Recovery Gains Momentum as R&D Engine Strengthens for 2027 Plan

IFF's Scent Recovery Fueled by Fine and Consumer Fragrance; 2027 R&D Plan

IFF Scent Recovery Gains Momentum in H2 2026, R&D Drives 2027 Plan

IFF Scent Recovery Gains Traction in 2H 2026, R&D Plan Supports 2027

IFF Scent Recovery Driven by R&D Upswing, 2H Fragrance Outlook, 2027 Plan